{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:56:32Z","timestamp":1780667792193,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002001","name":"DH | NIHR | Health Services and Delivery Research Programme","doi-asserted-by":"publisher","award":["SRF-2018-11-ST2-004)."],"award-info":[{"award-number":["SRF-2018-11-ST2-004)."]}],"id":[{"id":"10.13039\/501100002001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Long-term sequelae of COVID-19 remain critical public health concerns, with limited therapeutic options available. We conducted two case-control studies among COVID-19 infected individuals in the UK Biobank to explore the association of sociodemographic factors, clinical biomarkers, and comorbidities with the risk of two key phenotypes: Long COVID (LC, defined by patient self-report symptoms) and post-acute complications of SARS-CoV-2 infection (PACS, defined by clinical diagnosis), separately. Our study included 8,668 participants in the LC cohort (32% classified as cases) and 108,407 in the PACS cohort (with 2% being cases). Findings showed that age and sex were associated with both LC and PACS but in opposite directions. Additionally, obesity, socioeconomic deprivation, elevated C-reactive protein, triglyceride, vitamin D, HbA1c, cystatin C, urate, and alanine aminotransferase, and decreased HDL cholesterol and IGF-1, as well as CKD and COPD, were associated with LC. Most of these factors were also significant for PACS, except for alanine aminotransferase and vitamin D. These findings have potential mechanistic implications for the distinction between LC and PACS and can guide clinical implementation of identifying high-risk groups for targeted vaccination or other public health mitigation strategies.<\/jats:p>","DOI":"10.1038\/s41467-025-62354-0","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:18:44Z","timestamp":1753913924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sociodemographic factors, biomarkers and comorbidities associated with post-acute COVID-19 sequelae in UK Biobank"],"prefix":"10.1038","volume":"16","author":[{"given":"Marta","family":"Alcalde-Herraiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahed","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wildaliz","family":"Nieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marti","family":"Catala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-6346","authenticated-orcid":false,"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0040-0042","authenticated-orcid":false,"given":"Junqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"62354_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(23)00239-4","volume":"11","author":"M Parotto","year":"2023","unstructured":"Parotto, M. et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir. Med. 11, 739\u2013754 (2023).","journal-title":"Lancet Respir. Med."},{"key":"62354_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2213-2600(22)00169-2","volume":"10","author":"D Munblit","year":"2022","unstructured":"Munblit, D. et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir. Med. 10, 715\u2013724 (2022).","journal-title":"Lancet Respir. Med."},{"key":"62354_CR3","unstructured":"Office of National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk\/30march2023. Accessed 29\/05\/2025."},{"key":"62354_CR4","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.cell.2024.07.054","volume":"187","author":"MJ Peluso","year":"2024","unstructured":"Peluso, M. J. & Deeks, S. G. Mechanisms of long COVID and the path toward therapeutics. Cell 187, 5500\u20135529 (2024).","journal-title":"Cell"},{"key":"62354_CR5","unstructured":"Chippa, V., Aleem, A. & Anjum, F. Postacute coronavirus (COVID-19) syndrome. In: StatPearls. Treasure Island (FL) (2025)."},{"key":"62354_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601\u2013615 (2021).","journal-title":"Nat. Med."},{"key":"62354_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jamainternmed.2023.0750","volume":"183","author":"V Tsampasian","year":"2023","unstructured":"Tsampasian, V. et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern. Med. 183, 566\u2013580 (2023).","journal-title":"JAMA Intern. Med."},{"key":"62354_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1085988","volume":"10","author":"YJ Lai","year":"2023","unstructured":"Lai, Y. J. et al. Biomarkers in long COVID-19: a systematic review. Front. Med. (Lausanne) 10, 1085988 (2023).","journal-title":"Front. Med. (Lausanne)"},{"key":"62354_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.tem.2023.03.002","volume":"34","author":"S Turner","year":"2023","unstructured":"Turner, S. et al. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol. Metab. 34, 321\u2013344 (2023).","journal-title":"Trends Endocrinol. Metab."},{"key":"62354_CR10","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-022-01909-w","volume":"28","author":"A Subramanian","year":"2022","unstructured":"Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 28, 1706\u20131714 (2022).","journal-title":"Nat. Med."},{"key":"62354_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50495-7","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death. Nat. Commun. 15, 6363 (2024).","journal-title":"Nat. Commun."},{"key":"62354_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38315-2","volume":"13","author":"I Mogensen","year":"2023","unstructured":"Mogensen, I. et al. Post COVID-19 symptoms are common, also among young adults in the general population. Sci. Rep. 13, 11300 (2023).","journal-title":"Sci. Rep."},{"key":"62354_CR13","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1080\/03007995.2022.2081454","volume":"38","author":"SV Sylvester","year":"2022","unstructured":"Sylvester, S. V. et al. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr. Med. Res. Opin. 38, 1391\u20131399 (2022).","journal-title":"Curr. Med. Res. Opin."},{"key":"62354_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","volume":"588","author":"T Takahashi","year":"2020","unstructured":"Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315\u2013320 (2020).","journal-title":"Nature"},{"key":"62354_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626\u2013638 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"62354_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol 21, 133\u2013146 (2023).","journal-title":"Nat. Rev. Microbiol"},{"key":"62354_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-021-03553-9","volume":"594","author":"Z Al-Aly","year":"2021","unstructured":"Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259\u2013264 (2021).","journal-title":"Nature"},{"key":"62354_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S2213-8587(22)00355-2","volume":"11","author":"E Xu","year":"2023","unstructured":"Xu, E., Xie, Y. & Al-Aly, Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diab. Endocrinol. 11, 120\u2013128 (2023).","journal-title":"Lancet Diab. Endocrinol."},{"key":"62354_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.698169","volume":"12","author":"AD Proal","year":"2021","unstructured":"Proal, A. D. & VanElzakker, M. B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 12, 698169 (2021).","journal-title":"Front. Microbiol."},{"key":"62354_CR20","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","volume":"28","author":"Z Al-Aly","year":"2022","unstructured":"Al-Aly, Z., Bowe, B. & Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 28, 1461\u20131467 (2022).","journal-title":"Nat. Med."},{"key":"62354_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/heartjnl-2023-323483","volume":"110","author":"N Mercade-Besora","year":"2024","unstructured":"Mercade-Besora, N. et al. The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. Heart 110, 635\u2013643 (2024).","journal-title":"Heart"},{"key":"62354_CR22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","volume":"183","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern. Med. 183, 554\u2013564 (2023).","journal-title":"JAMA Intern. Med."},{"key":"62354_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28289","volume":"95","author":"YJ Chee","year":"2023","unstructured":"Chee, Y. J., Fan, B. E., Young, B. E., Dalan, R. & Lye, D. C. Clinical trials on the pharmacological treatment of long COVID: a systematic review. J. Med Virol. 95, e28289 (2023).","journal-title":"J. Med Virol."},{"key":"62354_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/d41586-022-02140-w","volume":"608","author":"H Ledford","year":"2022","unstructured":"Ledford, H. Long-COVID treatments: why the world is still waiting. Nature 608, 258\u2013260 (2022).","journal-title":"Nature"},{"key":"62354_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2213524119","volume":"119","author":"L Shaffer","year":"2022","unstructured":"Shaffer, L. Lots of long COVID treatment leads, but few are proven. Proc. Natl Acad. Sci. USA 119, e2213524119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"62354_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S2213-2600(23)00414-9","volume":"12","author":"M Catala","year":"2024","unstructured":"Catala, M. et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir. Med. 12, 225\u2013236 (2024).","journal-title":"Lancet Respir. Med."},{"key":"62354_CR27","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).","journal-title":"PLoS Med."},{"key":"62354_CR28","first-page":"mgen000397","volume":"6","author":"J Armstrong","year":"2020","unstructured":"Armstrong, J. et al. Dynamic linkage of COVID-19 test results between Public Health England\u2019s Second Generation Surveillance System and UK Biobank. Micro Genom. 6, mgen000397 (2020).","journal-title":"Micro Genom."},{"key":"62354_CR29","unstructured":"World Health Organization (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 29\/05\/2025."},{"key":"62354_CR30","unstructured":"National Health Service (NHS). Long-term effects of COVID-19 (long COVID). https:\/\/www.nhs.uk\/conditions\/covid-19\/long-term-effects-of-covid-19-long-covid\/. Accessed 29\/05\/2025."},{"key":"62354_CR31","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/s41591-023-02521-2","volume":"29","author":"B Bowe","year":"2023","unstructured":"Bowe, B., Xie, Y. & Al-Aly, Z. Postacute sequelae of COVID-19 at 2 years. Nat. Med. 29, 2347\u20132357 (2023).","journal-title":"Nat. Med."},{"key":"62354_CR32","doi-asserted-by":"publisher","first-page":"n1098","DOI":"10.1136\/bmj.n1098","volume":"373","author":"SE Daugherty","year":"2021","unstructured":"Daugherty, S. E. et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. Br. Med. J. 373, n1098 (2021).","journal-title":"Br. Med. J."},{"key":"62354_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","volume":"28","author":"Y Xie","year":"2022","unstructured":"Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 583\u2013590 (2022).","journal-title":"Nat. Med."},{"key":"62354_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S2213-8587(22)00044-4","volume":"10","author":"Y Xie","year":"2022","unstructured":"Xie, Y. & Al-Aly, Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diab. Endocrinol. 10, 311\u2013321 (2022).","journal-title":"Lancet Diab. Endocrinol."},{"key":"62354_CR35","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/s41591-022-02001-z","volume":"28","author":"E Xu","year":"2022","unstructured":"Xu, E., Xie, Y. & Al-Aly, Z. Long-term neurologic outcomes of COVID-19. Nat. Med. 28, 2406\u20132415 (2022).","journal-title":"Nat. Med."},{"key":"62354_CR36","doi-asserted-by":"publisher","first-page":"e068993","DOI":"10.1136\/bmj-2021-068993","volume":"376","author":"Y Xie","year":"2022","unstructured":"Xie, Y., Xu, E. & Al-Aly, Z. Risks of mental health outcomes in people with COVID-19: cohort study. Br. Med. J. 376, e068993 (2022).","journal-title":"Br. Med. J."},{"key":"62354_CR37","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1681\/ASN.2021060734","volume":"32","author":"B Bowe","year":"2021","unstructured":"Bowe, B., Xie, Y., Xu, E. & Al-Aly, Z. Kidney outcomes in long COVID. J. Am. Soc. Nephrol. 32, 2851\u20132862 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"62354_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36223-7","volume":"14","author":"E Xu","year":"2023","unstructured":"Xu, E., Xie, Y. & Al-Aly, Z. Long-term gastrointestinal outcomes of COVID-19. Nat. Commun. 14, 983 (2023).","journal-title":"Nat. Commun."},{"key":"62354_CR39","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamainternmed.2022.3858","volume":"182","author":"J Xie","year":"2022","unstructured":"Xie, J. et al. Clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory patients with COVID-19. JAMA Intern. Med. 182, 1063\u20131070 (2022).","journal-title":"JAMA Intern. Med."},{"key":"62354_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"key":"62354_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S Buuren","year":"2011","unstructured":"Buuren, S. & Groothuis-Oudshoorn, K. mice: Multivariate Imputation by Chained Equations in R. J. Stat. Softw. 45, 1\u201367 (2011).","journal-title":"J. Stat. Softw."},{"key":"62354_CR42","unstructured":"Wickham, H. F. R., Henry, L., M\u00fcller, K. & Vaughan, D. dplyr: A Grammar of Data Manipulation. R package. https:\/\/github.com\/tidyverse\/dplyr (2023)."},{"key":"62354_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1467-985X.2010.00676_9.x","volume":"174","author":"C Ginestet","year":"2011","unstructured":"Ginestet, C. ggplot2: Elegant Graphics for Data Analysis. J. R. Stat. Soc. Ser. A174, 245\u2013246 (2011).","journal-title":"J. R. Stat. Soc. Ser. A"},{"key":"62354_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 (2010).","journal-title":"J. Stat. Softw."},{"key":"62354_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i01","volume":"106","author":"JK Tay","year":"2023","unstructured":"Tay, J. K., Narasimhan, B. & Hastie, T. Elastic net regularization paths for all generalized linear models. J. Stat. Softw. 106, 1 (2023).","journal-title":"J. Stat. Softw."},{"key":"62354_CR46","doi-asserted-by":"publisher","unstructured":"Alcalde-Herraiz, M. Determinants of LC and PACS. GitHub Repository (https:\/\/doi.org\/10.5281\/zenodo.15969174) https:\/\/github.com\/oxford-pharmacoepi\/DeterminantsLC_PACS (2025).","DOI":"10.5281\/zenodo.15969174"},{"key":"62354_CR47","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/aje\/kwae087","volume":"193","author":"SV Wang","year":"2024","unstructured":"Wang, S. V. & Pottegard, A. Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research. Am. J. Epidemiol. 193, 1625\u20131631 (2024).","journal-title":"Am. J. Epidemiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62354-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62354-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62354-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:50:07Z","timestamp":1757321407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62354-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62354"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62354-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DPA research group from the University of Oxford has received research grants from the European Medicines Agency, from the Innovative Medicines Initiative, from Gilead Science, and from UCB Biopharma. S.I., J.J.W., W.N., Y.L., and M.B. are employees of Gilead Sciences and may own stock in the company. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7009"}}